Russell Investments Group
MRVI icon

Russell Investments Group’s Maravai LifeSciences MRVI Stock Holding History

Russell Investments Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Buy
138,743
+6,002
+5% +$20.3K ﹤0.01% 2598
2025
Q4 		$431K Buy
132,741
+20,434
+18% +$68.8K ﹤0.01% 2543
2025
Q3 		$322K Buy
112,307
+71,961
+178% +$184K ﹤0.01% 2640
2025
Q2 		$97.2K Sell
40,346
-304
-0.7% -$639 ﹤0.01% 2821
2025
Q1 		$89.8K Buy
+40,650
New +$161K ﹤0.01% 2781
2024
Q3 		– Sell
-1,577
Closed -$11.3K – 3755
2024
Q2 		$11.3K Sell
1,577
-11,604
-88% -$100K ﹤0.01% 3046
2024
Q1 		$114K Sell
13,181
-99,415
-88% -$673K ﹤0.01% 2556
2023
Q4 		$738K Buy
112,596
+112,417
+62,803% +$726K ﹤0.01% 2089
2023
Q3 		$1.79K Buy
179
+153
+588% +$1.68K ﹤0.01% 3274
2023
Q2 		$323 Sell
26
-2,800
-99% -$37.8K ﹤0.01% 3389
2023
Q1 		$39.6K Sell
2,826
-20,959
-88% -$301K ﹤0.01% 2739
2022
Q4 		$340K Buy
+23,785
New +$375K ﹤0.01% 2427

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Russell Investments Group's MRVI Position: Q1 2026 in Review

Russell Investments Group increased its Maravai LifeSciences (MRVI) stake by 4.5% in Q1 2026, buying an estimated $20.3K and bringing the position to 138,743 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

Russell Investments Group first reported a position in MRVI in Q4 2022 and has held it in 12 quarters since. The position peaked at $738K in Q4 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Russell Investments Group held 138,743 shares of Maravai LifeSciences worth $393K as of Q1 2026.
  • Russell Investments Group bought 6,002 Maravai LifeSciences shares in Q1 2026, an estimated $20.3K.
  • Maravai LifeSciences made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2598 holding.
  • Russell Investments Group first reported a position in Maravai LifeSciences in Q4 2022 and has held it in 12 quarters since.
  • Russell Investments Group's Maravai LifeSciences position peaked at $738K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.